Erythropoietin (EPO) Drugs Market to See Negative Growth in the Offing, Predicts Koncept Analytics in Its Report Available at MarketPublishers.com
17 Nov 2016 • by Natalie Aster
LONDON – In the upcoming years, the world’s erythropoietin (EPO) drugs market is anticipated to witness negative growth, majorly owing to expiry of 2 most common EPO drugs, darbepoetin-alfa and epoetin-alfa, allowin the entry of biosimilars, which will likely present a serious challenge to EPO drugs market.
However, positive growth rates will likely be registered in the APAC regional market for EPO drugs in the years ahead. This boom period is expected to be encouraged by favourable government medical reimbursement policies and also rising disposable incomes of the local population.
Johnson & Johnson, Teva Pharmaceutical Industries Limited, Amgen and Roche are major players in the world’s EPO drugs market.
The research study titled “Global Erythropoietin (EPO) Market with Focus on Asia: Industry Analysis & Outlook (2016-2020)” drawn up by Koncept Analytics comprises a granular unbiased analysis of the world erythropoietin (EPO) market landscape, touches upon the key influencing factors, explores the main market segments and also covers the regulative framework. The report focuses on the scenario in the US and APAC markets for EPO drugs. This study features prevailing and emerging trends, discusses important industry aspects and issues, reviews competitive environment and uncovers vital details on top players. The report contains insights into the historical background and present scenario and, further, gives access to future outlook.
Many other in-demand research publications by the publisher are available at the Koncept Analytics page.